Related Experiment Video

Updated: Jun 20, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer

Masahide Matsuyama1, Rikio Yoshimura

  • 1Department of Urology, Osaka City University Graduate School of Medicine, Osaka, Japan.

Biologics : Targets & Therapy
|August 27, 2009
PubMed

Insights

Nonsteroidal anti-inflammatory drugs (NSAIDs) may inhibit cancer by targeting cyclooxygenase (COX) and lipoxygenase (LOX) enzymes. These drugs also modulate peroxisome proliferator activator-receptor gamma (PPAR-gamma), a factor in cell growth and carcinogenesis.

Area of Science:

  • Molecular Biology
  • Oncology
  • Pharmacology

Background:

  • Epidemiological and animal studies indicate nonsteroidal anti-inflammatory drugs (NSAIDs) decrease colorectal carcinoma incidence.
  • Cyclooxygenase (COX) and lipoxygenase (LOX) are key enzymes in arachidonic acid metabolism, potentially involved in carcinogenesis.
  • Peroxisome proliferator activator-receptor gamma (PPAR-gamma) is a nuclear receptor implicated in adipogenesis and cancer development.

Purpose of the Study:

  • To review the expression of COX-2, LOX, and PPAR-gamma in human prostate cancer.
  • To examine the effects of COX-2 and LOX inhibitors on cancer.
  • To investigate the role of PPAR-gamma ligands in cancer modulation.

Main Methods:

  • Review of existing epidemiological studies and animal experiments.
  • Analysis of expression data for COX-2, LOX, and PPAR-gamma in prostate cancer tissues.
  • Evaluation of the impact of specific inhibitors and ligands on cellular processes.

Main Results:

  • NSAIDs' inhibition of COX enzymes is a proposed mechanism for cancer risk reduction.
  • LOX enzymes, like COX, may contribute to cancer initiation and promotion.
  • PPAR-gamma is identified as a target for NSAID-mediated cell growth modulation.

Conclusions:

  • COX-2, LOX, and PPAR-gamma are relevant targets in prostate cancer research.
  • Inhibitors of COX and LOX, along with PPAR-gamma ligands, show potential in cancer therapy.
  • Further research is warranted to elucidate the precise roles of these molecules in carcinogenesis.
Keywords:
cyclooxygenaselipoxygenaseperoxisome proliferator activator-receptor-γprostate cancer

More Related Videos

Quantitative Analysis of Autophagy using Advanced 3D Fluorescence Microscopy09:59

Quantitative Analysis of Autophagy using Advanced 3D Fluorescence Microscopy

Published on: May 3, 2013

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...